8-K: Chimerix Pauses U.S. Enrollment in Phase 3 ACTION Study Amidst FDA Review of Dordaviprone

Chimerix, Inc. will pause enrollment in the U.S. portion of its Phase 3 ACTION study for dordaviprone due to the ongoing FDA review of its New Drug Application (NDA).

Summary

• Chimerix, Inc. is pausing enrollment in the U.S. portion of the Phase 3 ACTION study for dordaviprone.
• This decision is due to the FDA's review of the NDA for dordaviprone, which has a PDUFA target action date of August 18, 2025.
• The pause aims to mitigate potential confounding factors during the NDA review period.
• Eligible U.S. patients can choose between ACTION trial enrollment or accessing dordaviprone via the U.S. expanded access program during the NDA review period.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the FDA acceptance of the NDA is positive, the enrollment pause introduces uncertainty about the study's timeline. The availability of an expanded access program is a mitigating factor.

Positives

• The FDA has accepted Chimerix's NDA for dordaviprone, indicating progress in the regulatory pathway.
• An expanded access program offers an alternative for patients during the enrollment pause.

Negatives

• The pause in U.S. enrollment could potentially delay the completion of the Phase 3 ACTION study.

Risks

• The ultimate approval of dordaviprone is subject to FDA review and may not be granted.
• The Phase 3 ACTION study's outcome is uncertain and may not be positive.
• Market acceptance of dordaviprone, if approved, is not guaranteed.
• The company's cash runway and market conditions could impact its ability to execute its plans.

Future Outlook

The company is awaiting the FDA's decision on the NDA for dordaviprone, with a PDUFA target action date of August 18, 2025, and is managing the Phase 3 ACTION study enrollment in light of this review.

Management Comments

• The company is pausing enrollment in the U.S. portion of the ACTION study to mitigate potential confounding during the NDA review period.

Industry Context

This announcement reflects the typical regulatory process for pharmaceutical companies seeking drug approval, including the interaction with the FDA and the management of clinical trials during the review period.

Comparison to Industry Standards

• Pausing enrollment during NDA review is a common practice in the pharmaceutical industry to ensure data integrity.
• Expanded access programs are often implemented to provide patients with access to investigational drugs while awaiting regulatory decisions.
• The PDUFA target action date is a standard timeline set by the FDA for reviewing new drug applications, comparable to timelines for other companies seeking drug approval.

Stakeholder Impact

• Patients in the U.S. may experience a change in their enrollment options for the ACTION study.
• Shareholders may be impacted by the potential delay in the study's completion.
• The company's employees involved in the ACTION study may experience adjustments to their work.

Next Steps

• The company will await the FDA's decision on the dordaviprone NDA.
• The company will continue the Phase 3 ACTION study outside of the U.S.
• The company will manage the expanded access program for eligible U.S. patients.

Key Dates